Compare

LeMaitre Vascular/$LMAT

1D1W1M3M6MYTD1Y5YMAX

About LeMaitre Vascular

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Ticker
$LMAT
Sector
Health
Primary listing
NASDAQ
Employees
651

LMAT Metrics

BasicAdvanced
$1.7B
26.77
$2.75
0.49
$0.95
1.36%

What the Analysts think about LMAT

Analyst ratings (Buy, Hold, Sell) for LeMaitre Vascular stock.
Analyst projections of the future price of LeMaitre Vascular stock.

Bulls say / Bears say

Q3 organic sales rose 12%, with both pricing and unit growth contributing, and management maintained an 11% organic growth outlook for 2026. It expects adjusted EPS to grow 18% this year. (LeMaitre)
Biologics are a growing product engine: Q3 Artegraft sales rose 18% and RestoreFlow allograft sales rose 34%. Artegraft is now approved in 60 countries, giving its international launch room to expand. (The Motley Fool)
The B. Braun asset purchase adds grafts and other vascular products that generated $9.4 million in sales in 2025. LeMaitre plans to use its expanding international sales force to grow the portfolio as customer contracts transfer. (LeMaitre)
Q3 adjusted EPS of $0.65 missed the $0.69 estimate, while gross margin of 71.7% was below the 72.1% forecast. Management also trimmed its full-year gross-margin outlook to 72.1% from 72.4%. (Investing.com, The Motley Fool)
The B. Braun products may take 18–24 months to move into LeMaitre’s sales channel, and the company warned of possible back orders during the manufacturing handover. Management also floated possible first-year customer losses of 10%–15%. (The Motley Fool)
Growth in RestoreFlow is being held back by quality-control processing capacity, so the company has not been able to meet all demand. An FDA reinspection of the Artegraft facility is also likely in 2027, leaving a further regulatory execution risk. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.

LMAT Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

LMAT Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.